

Number of COVID Cases in Delhi Crashes after Mass Distribution of Ivermectin

By [Thomas Lifson](#)

Asia-Pacific Research, May 31, 2021

[American Thinker](#) 29 May 2021

Region: [South Asia](#)

Theme: [Science](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at [@crg_globalresearch](#).

India has been suffering horrendously from COVID of late, and the complete death toll may never be known. But in the capital city of Delhi, mass distribution of ivermectin began and the results have been stunning.

Stephen McIntyre of Climate Audit posted a [Twitter thread](#) that includes this remarkable graph:

amazing numbers in Delhi if true. I dont understand why medical political establishment hates ivermectin so much and loves masks so much.
<https://t.co/GThcqsrN52>

— Stephen McIntyre (@ClimateAudit) [May 27, 2021](#)



[Source](#)

This result is consistent with the results of mass distribution of ivermectin in Mexico City, as [reported by James V. DeLong](#) on these pages on May 21, 2021:



Yet, most doctors in this country refuse to prescribe ivermectin, and most hospitals in this country refuse to administer it even to seriously ill COVID patients, citing the lack of double-blind studies – which are expensive and time consuming and which yield no big profits for anyone since ivermectin is a generic drug with no patent protection.

A Buffalo, NY woman had to sue in order to receive ivermectin therapy while hospitalized, forced to bear considerable legal fees. After a judge ordered that she receive it, [she](#)

[recovered](#) and left the hospital.

In poorer countries, where vaccines are unavailable to too expensive for mass use, they have been forced to resort to ivermectin. This has had the effect of conducting a mass experiment (albeit not with the double-blind, randomized, controlled conditions that “gold standard” medical research requires. Maybe that will enable the ivermectin deniers to maintain their posture of self-righteousness.

Note that the emergency use authorization under which the experimental mRNA vaccines have been approved for mass use would not be given if there were an accepted effective alternative therapy. Billions of dollars flowing into the hands of vaccine makers would not have happened.

Disclaimer: Of course, I am not a medical doctor and am not qualified to offer medical advice. This post is only meant to provide information, and not to recommend any medical treatment to any readers.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from Countercurrents

The original source of this article is [American Thinker](#)
Copyright © [Thomas Lifson](#), [American Thinker](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Thomas Lifson](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). Asia-Pacific Research will not be responsible for any inaccurate or incorrect statement in this article. Asia-Pacific Research grants permission to cross-post Asia-Pacific Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Asia-Pacific Research article. For publication of Asia-Pacific Research articles in print or other forms including commercial internet sites, contact: editors@asia-pacificresearch.com

www.asia-pacificresearch.com contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: editors@asia-pacificresearch.com